ENXTBR:HYLPharmaceuticals
Hyloris Pharmaceuticals ENXTBR HYL Loss Near €3.6 Million Tests Bullish Profitability Narratives
Hyloris Pharmaceuticals FY 2025 earnings snapshot
Hyloris Pharmaceuticals (ENXTBR:HYL) has opened FY 2025 with first half revenue of €3.339 million and a basic EPS loss of €0.13, setting the tone for another year where growth ambitions still sit alongside negative earnings. The company has seen revenue move from €4.64 million in the first half of 2024 to €5.12 million in the second half of 2024, with basic EPS losses of €0.12 and roughly €0.11 per share across those periods. This frames a...